S&P 500   3,661.89 (-0.02%)
DOW   29,798.49 (-0.09%)
QQQ   303.35 (-0.04%)
AAPL   122.98 (+0.21%)
MSFT   214.02 (-1.01%)
FB   288.70 (+0.75%)
GOOGL   1,820.73 (+1.41%)
AMZN   3,214.30 (-0.18%)
TSLA   562.64 (-3.78%)
NVDA   541.63 (+1.13%)
BABA   261.89 (-0.80%)
CGC   28.13 (+5.55%)
GE   10.39 (+2.36%)
MU   68.90 (+2.71%)
AMD   94.54 (+2.06%)
T   28.95 (+0.28%)
NIO   46.16 (+1.76%)
F   9.20 (-0.43%)
ACB   10.75 (+10.26%)
NFLX   503.17 (-0.28%)
BA   219.03 (+2.83%)
GILD   61.40 (+0.46%)
DIS   152.13 (+1.80%)
S&P 500   3,661.89 (-0.02%)
DOW   29,798.49 (-0.09%)
QQQ   303.35 (-0.04%)
AAPL   122.98 (+0.21%)
MSFT   214.02 (-1.01%)
FB   288.70 (+0.75%)
GOOGL   1,820.73 (+1.41%)
AMZN   3,214.30 (-0.18%)
TSLA   562.64 (-3.78%)
NVDA   541.63 (+1.13%)
BABA   261.89 (-0.80%)
CGC   28.13 (+5.55%)
GE   10.39 (+2.36%)
MU   68.90 (+2.71%)
AMD   94.54 (+2.06%)
T   28.95 (+0.28%)
NIO   46.16 (+1.76%)
F   9.20 (-0.43%)
ACB   10.75 (+10.26%)
NFLX   503.17 (-0.28%)
BA   219.03 (+2.83%)
GILD   61.40 (+0.46%)
DIS   152.13 (+1.80%)
S&P 500   3,661.89 (-0.02%)
DOW   29,798.49 (-0.09%)
QQQ   303.35 (-0.04%)
AAPL   122.98 (+0.21%)
MSFT   214.02 (-1.01%)
FB   288.70 (+0.75%)
GOOGL   1,820.73 (+1.41%)
AMZN   3,214.30 (-0.18%)
TSLA   562.64 (-3.78%)
NVDA   541.63 (+1.13%)
BABA   261.89 (-0.80%)
CGC   28.13 (+5.55%)
GE   10.39 (+2.36%)
MU   68.90 (+2.71%)
AMD   94.54 (+2.06%)
T   28.95 (+0.28%)
NIO   46.16 (+1.76%)
F   9.20 (-0.43%)
ACB   10.75 (+10.26%)
NFLX   503.17 (-0.28%)
BA   219.03 (+2.83%)
GILD   61.40 (+0.46%)
DIS   152.13 (+1.80%)
S&P 500   3,661.89 (-0.02%)
DOW   29,798.49 (-0.09%)
QQQ   303.35 (-0.04%)
AAPL   122.98 (+0.21%)
MSFT   214.02 (-1.01%)
FB   288.70 (+0.75%)
GOOGL   1,820.73 (+1.41%)
AMZN   3,214.30 (-0.18%)
TSLA   562.64 (-3.78%)
NVDA   541.63 (+1.13%)
BABA   261.89 (-0.80%)
CGC   28.13 (+5.55%)
GE   10.39 (+2.36%)
MU   68.90 (+2.71%)
AMD   94.54 (+2.06%)
T   28.95 (+0.28%)
NIO   46.16 (+1.76%)
F   9.20 (-0.43%)
ACB   10.75 (+10.26%)
NFLX   503.17 (-0.28%)
BA   219.03 (+2.83%)
GILD   61.40 (+0.46%)
DIS   152.13 (+1.80%)
Log in
ARCA:DXR

Daxor Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume1,554 shs
Market Capitalization$54.44 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.83
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.71 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone212 330 8500
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$54.44 million
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive DXR News and Ratings via Email

Sign-up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Daxor (ARCA:DXR) Frequently Asked Questions

What stocks does MarketBeat like better than Daxor?

Wall Street analysts have given Daxor a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Daxor wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Daxor's key competitors?

Who are Daxor's key executives?

Daxor's management team includes the following people:
  • Mr. Michael Richard Feldschuh, Chairman, Pres & CEO (Age 51, Pay $100k)
  • Mr. Jonathan Adam Feldschuh, Chief Scientific Officer & Director (Age 55, Pay $127.92k)
  • Mr. Robert J. Michel M.B.A., CPA, CPA, CFO, Chief Compliance Officer & Corp. Sec. (Age 63)
  • Ms. Kathryn A. Kornafel, VP of Marketing & Commercial Devel.
  • Mr. Guido Manzo, VP of Sales

What is Daxor's stock symbol?

Daxor trades on the ARCA under the ticker symbol "DXR."

How do I buy shares of Daxor?

Shares of DXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Daxor?

Daxor has a market capitalization of $0.00.

What is Daxor's official website?

The official website for Daxor is www.daxor.com.

How can I contact Daxor?

Daxor's mailing address is 350 FIFTH AVENUE SUITE 7120, NEW YORK NY, 10118. The company can be reached via phone at 212 330 8500 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.